Vyome Holdings

HIND · NASDAQ

$1.84+$0.00 (+0.00%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $1.84

About HIND

Vyome Holdings, Inc. engages in the development of immuno-inflammatory assets. The company is headquartered in San Clemente, California and currently employs 9 full-time employees. The company went IPO on 2016-10-06. The firm is focused on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. Its clinical program VT1953 Gel is focused on cancer patients who are suffering from malignant fungating wounds (MFW). Its preclinical development program, VT1908, is a non-steroidal eye drop, which is focused on Uveitis. Its other business unit is focused on offering artificial intelligence (AI)-driven healthcare solutions across mental health and inflammation care, digital therapeutics and psychoneuroimmunology.

Employees: 9
Headquarters: San Clemente, California
Listed: Oct 6, 2016
Sector: Health Care
Industry: Pharmaceuticals
Website: reshapelifesciences.com

Leadership

Vyome Holdings executives
Name	Title	Since	Age
Krishna Gupta	—	2025	—
Venkateswarlu Nelabhotla	—	2025	63
Robert Dickey	—	—	—
Mohanjit Jolly	—	—	—
Stash Pomichter	—	—	—
Shiladitya Sengupta	—	—	—
John Tincoff	—	—	—
Lori Mcdougal	—	—	—
Arda Minocherhomjee	—	—	71

Similar companies

Companies in the same industry as Vyome Holdings

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.